Common painkillers linked to increased risk of heart problems

Jan 11, 2011

Commonly used painkillers for treating inflammation can increase the risk of heart attacks and strokes, according to an analysis of the evidence published in the British Medical Journal today.

The drugs include traditional non-steroidal anti-inflammatory drugs (NSAIDS) as well as new generation anti-inflammatory drugs, known as COX-2 inhibitors.

The researchers say that doctors and patients need to be aware that prescription of any anti-inflammatory drug needs to take cardiovascular risk into account.

NSAIDs have been the cornerstone of managing pain in patients with osteoarthritis and other painful conditions. In 2004, the COX-2 inhibitor rofecoxib was withdrawn from the market after a trial found that the drug increased the risk of cardiovascular disease. Since then, there has been much debate about the cardiovascular safety of COX-2 inhibitors and traditional NSAIDs, which several studies have not been able to resolve.

So researchers in Switzerland performed a comprehensive analysis of all randomised controlled trials comparing any NSAID with other NSAIDs or placebo.

They included 31 trials and 116,429 patients taking seven different drugs (naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib, lumiracoxib) or placebo to provide a more reliable estimate of the cardiovascular risks of these drugs than previous studies.

Overall, the number of harmful outcomes that could be compared for placebo versus treatment was low. In 29 trials there was a total of 554 heart attacks; in 26 trials there were 377 strokes, and in 28 trials there were 676 deaths. So the absolute risk of among people taking was low, but the researchers did find that, relative to placebo, the drugs carried important risks.

For instance, compared with placebo, rofecoxib and lumiracoxib were associated with twice the risk of , while ibuprofen was associated with more than three times the risk of stroke. Etoricoxib and diclofenac were associated with the highest (around four times) risk of cardiovascular death.

Naproxen appeared least harmful in terms of cardiovascular safety among the seven analysed preparations.

Although the number of cardiovascular events in the trials was low, the authors say "our study provides the best available evidence on the safety of this class of drugs." They conclude: "Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug."

An accompanying editorial says these cardiovascular risks are worrying because many patients have both cardiovascular disease and musculoskeletal disease, and suggests that it is time for an evaluation of a broader range of alternatives.

Explore further: Deaths from narcotic painkillers quadrupled in past decade, CDC reports

add to favorites email to friend print save as pdf

Related Stories

Ibuprofen puts high risk cardiac patients at risk

Apr 05, 2007

Doctors who treat the painful condition of osteoarthritis in patients with increased cardiovascular risk need to be cautious. A team lead by researchers at Mount Sinai School of Medicine, are the first to study outcomes in ...

Reducing side-effects of painkillers

Sep 12, 2006

Cardiff University researchers have increased the understanding of why some painkillers increase the risk of heart attack and stroke.

New research to reduce drug side-effects

Jul 09, 2009

They are a group of drugs which millions of people rely on to keep pain at bay but they can have unwanted side-effects which are sometimes more serious than the original health problem. Now scientists at The University of ...

Recommended for you

Big cities take aim at prescription painkillers

22 hours ago

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

Sep 16, 2014

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

CarolinaScotsman
5 / 5 (2) Jan 11, 2011
" Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug."

Isn't aspirin a non-steroidal anti-inflammatory drug? Isn't it routinely prescribed to help prevent heart attacks? I suspect much more research needs to be done before one paints the enitre class of NSAIDS with the same brush as the cox-2 inhibitors.
ormondotvos
not rated yet Jan 13, 2011
Scare science.